Selective depletion of plasma cells secreting pathogenic autoantibodies in chronic autoimmune diseases – a potentially curative therapeutic approach (PCdepCAD)

Leibniz Transfer

Using B-cell-depleting antibodies has led to promising results in the past in the treatment of autoimmune diseases. However, a drawback of these therapies is the depletion of plasma cells that secrete autoantigen-specific antibodies. The leader of the transfer project will continue to work on an affinity matrix he developed that can isolate antigen-specific plasma cells and deplete them. If this method, thought by experts to be almost impossible, succeeds, it would represent a key breakthrough in the treatment of B-cell-mediated autoimmune disease.

Cooperating partners: Charité – Universitätsmedizin Berlin; Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP)

Project term: since 2021